Exemplification of the challenges associated with utilising fluorescence intensity based assays in discovery
暂无分享,去创建一个
[1] M. Weir. Renin inhibitors: novel agents for renoprotection or a better angiotensin receptor blocker for blood pressure lowering? , 2007, Current opinion in nephrology and hypertension.
[2] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[3] A. Berger,et al. Mapping the active site of papain with the aid of peptide substrates and inhibitors. , 1970, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[4] Venkataraman Thanabal,et al. SRT1720, SRT2183, SRT1460, and Resveratrol Are Not Direct Activators of SIRT1♦ , 2010, The Journal of Biological Chemistry.
[5] C. Fahy,et al. Processing of peptide and hormone precursors at the dibasic cleavage sites , 2009, Cellular and Molecular Life Sciences.
[6] P. Coleman,et al. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. , 1981, Methods in enzymology.
[7] Roland Martin. Multiple sclerosis: Closing in on an oral treatment , 2010, Nature.
[8] V. Schramm,et al. SIR2: the biochemical mechanism of NAD(+)-dependent protein deacetylation and ADP-ribosyl enzyme intermediates. , 2004, Current medicinal chemistry.
[9] A. Hopkins,et al. Navigating chemical space for biology and medicine , 2004, Nature.
[10] Xiayang Qiu,et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia , 2007, Nature Structural &Molecular Biology.
[11] Eric David,et al. Pharmaceutical R&D: the road to positive returns , 2009, Nature Reviews Drug Discovery.
[12] G. Baldwin,et al. Peptide processing and biology in human disease , 2009, Current opinion in endocrinology, diabetes, and obesity.
[13] A. Berger,et al. On the active site of proteases. 3. Mapping the active site of papain; specific peptide inhibitors of papain. , 1968, Biochemical and biophysical research communications.
[14] Walters Wp,et al. Guiding molecules towards drug-likeness. , 2002 .
[15] Brian C. Smith,et al. Mechanisms and molecular probes of sirtuins. , 2008, Chemistry & biology.
[16] Dependence of the P2-S2 stereochemical selectivity of papain on the nature of the catalytic-site chemistry. Quantification of selectivity in the catalysed hydrolysis of the enantiomeric N-acetylphenylalanylglycine 4-nitroanilides. , 1990, The Biochemical journal.
[17] Amy V. Lynch,et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.
[18] Mariano Ruiz Espejo. Book Review: Clinical trials. A methodologic perspective, 2nd edition , 2006 .
[19] J. Kraut,et al. An x-ray crystallographic study of the binding of peptide chloromethyl ketone inhibitors to subtilisin BPN'. , 1972, Biochemistry.
[20] J. Kraut,et al. Polypeptide halomethyl ketones bind to serine proteases as analogs of the tetrahedral intermediate. X-ray crystallographic comparison of lysine- and phenylalanine-polypeptide chloromethyl ketone-inhibited subtilisin. , 1976, The Journal of biological chemistry.
[21] Sergei A Eremin,et al. Fluorescence polarization immunoassays and related methods for simple, high-throughput screening of small molecules , 2008, Analytical and bioanalytical chemistry.
[22] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[23] Christopher P Austin,et al. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. , 2010, Journal of medicinal chemistry.
[24] B. Munos. Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.
[25] N. Hooper,et al. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor , 2009, The Biochemical journal.
[26] B. Ozenberger,et al. Functional characterization of Narc 1, a novel proteinase related to proteinase K. , 2003, Archives of biochemistry and biophysics.
[27] C. Craik,et al. Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[28] Christopher P Austin,et al. A high-throughput screen for aggregation-based inhibition in a large compound library. , 2007, Journal of medicinal chemistry.
[29] C. G. Knight. [2] Fluorimetric assays of proteolytic enzymes , 1995 .
[30] R. Parker,et al. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.
[31] Phuong Chung,et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan , 2003, Nature.
[32] David A. Calhoun,et al. Drugs targeting the renin–angiotensin–aldosterone system , 2002, Nature Reviews Drug Discovery.
[33] C. G. Knight. Fluorimetric assays of proteolytic enzymes. , 1995, Methods in enzymology.
[34] C. Porte,et al. Saquinavir, the pioneer antiretroviral protease inhibitor , 2009, Expert opinion on drug metabolism & toxicology.
[35] J. Holst,et al. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? , 2004, Expert opinion on investigational drugs.
[36] John T. Powers,et al. Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors , 2010, Nature.
[37] K. Pruitt,et al. The role of sirtuin proteins in obesity. , 2008, Pathophysiology : the official journal of the International Society for Pathophysiology.
[38] E. Trinquet,et al. HTRF: A Technology Tailored for Drug Discovery –A Review of Theoretical Aspects and Recent Applications , 2009, Current chemical genomics.
[39] G. Feuerstein,et al. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality. , 2009, Biochemical pharmacology.
[40] A. Berger,et al. On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.
[41] L. Lau,et al. Fas-Mediated Apoptosis Is Regulated by the Extracellular Matrix Protein CCN1 (CYR61) In Vitro and In Vivo , 2009, Molecular and Cellular Biology.
[42] V. Kaushik,et al. Mass spectrometric techniques for label-free high-throughput screening in drug discovery. , 2007, Analytical chemistry.
[43] M. Murcko,et al. Guiding molecules towards drug-likeness. , 2002, Current opinion in drug discovery & development.
[44] Andrew B. Hughes. Amino acids, peptides and proteins in organic chemistry , 2009 .
[45] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[46] D. Sinclair,et al. Mammalian sirtuins: biological insights and disease relevance. , 2010, Annual review of pathology.
[47] S. Oparil,et al. Purification and assay methods for angiotensin-converting enzyme. , 1996, Journal of chromatography. A.
[48] S. Piantadosi. Clinical Trials : A Methodologic Perspective , 2005 .
[49] N. Hooper,et al. A broad‐spectrum fluorescence‐based peptide library for the rapid identification of protease substrates , 2006, Proteomics.
[50] M. Bottomley,et al. Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants* , 2009, Journal of Biological Chemistry.
[51] O. Ornatsky,et al. Development of inductively coupled plasma-mass spectrometry-based protease assays. , 2010, Analytical biochemistry.
[52] Shu-Chen Lu,et al. Resveratrol is Not a Direct Activator of SIRT1 Enzyme Activity , 2009, Chemical biology & drug design.
[53] A. Prat,et al. The activation and physiological functions of the proprotein convertases. , 2008, The international journal of biochemistry & cell biology.
[54] C. Betzel,et al. Three-dimensional structure of proteinase K at 0.15-nm resolution. , 1988, European journal of biochemistry.
[55] Andreas Sewing,et al. Fluorescence readouts in HTS: no gain without pain? , 2003, Drug discovery today.
[56] M J Todd,et al. Enzyme kinetics determined using calorimetry: a general assay for enzyme activity? , 2001, Analytical biochemistry.
[57] Jacques Neefjes,et al. Fluorescent probes for proteolysis: Tools for drug discovery , 2004, Nature Reviews Drug Discovery.
[58] M. Hsu,et al. Mechanism of the Maturation Process of SARS-CoV 3CL Protease , 2005, Journal of Biological Chemistry.
[59] Ronald T Raines,et al. Bright ideas for chemical biology. , 2008, ACS chemical biology.
[60] Taosheng Chen,et al. A Practical Guide to Assay Development and High-Throughput Screening in Drug Discovery , 2009 .
[61] James Inglese,et al. A specific mechanism for nonspecific activation in reporter-gene assays. , 2008, ACS chemical biology.
[62] K Dodgson,et al. A 100K well screen for a muscarinic receptor using the Epic® label-free system – a reflection on the benefits of the label-free approach to screening seven-transmembrane receptors , 2009, Journal of receptor and signal transduction research.
[63] D. Fairlie,et al. Protease inhibitors in the clinic. , 2005, Medicinal chemistry (Shariqah (United Arab Emirates)).